Day: October 26, 2022

On January 28, 2021, Cuthbertson, Alan; Boehnke, Niels published a patent.HPLC of Formula: 282734-37-6 The title of the patent was Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer. And the patent contained the following:

The invention is related to the preparation of compounds I [n = 1-3; R1-4 = OH or Q; Q = a tissue-targeting moiety selected from the group consisting of poly- and oligopeptides, proteins, DNA and RNA fragments, aptamers polyclonal or monoclonal antibodies, and a mixture of proteins or fragments or constructs of protein] their stereoisomers, hydrates, solvates and salts, and targeted radiopharmaceuticals, pharmaceutical compositions and combinations comprising them and their use for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients. The experimental process involved the reaction of (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-bromopyridin-2-yl)propanoic acid(cas: 282734-37-6).HPLC of Formula: 282734-37-6

The Article related to peptide chelator conjugate preparation antitumor prostate cancer, preparation peptide chelator thorium 227 her2 fap psma conjugate, prostate specific membrane antigen carboxy hopo thorium 227 conjugate, targeted radiopharmaceutical prostate cancer and other aspects.HPLC of Formula: 282734-37-6

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On June 5, 2014, Walsh, Shawn P.; Cato, Brian; Frie, Jessica L.; Kim, Dooseop; Pasternak, Alexander; Shi, Zhi-Cai published a patent.Recommanded Product: 868551-99-9 The title of the patent was Preparation of piperidine derivatives as inhibitors of the renal outer medullary potassium channel for treating cardiovascular diseases and edematous conditions. And the patent contained the following:

The present invention provides compounds of Formula I (wherein n = 0-1; the N-containing ring system is (un)substituted piperidinyl, etc.; R1 is -H, -OC1-3alkyl or -OH; R2 is -H or C1-3alkyl; R3 is -H, -F, -C1-3 alkyl or phenyl; or when n is 0, R2 and R3 are joined together to form a 4-6 member ring with the nitrogen and carbon to which each is attached; R4 and R5 are each independently -H or -C1-3-alkyl, or R4 and R5 are joined together with the carbon to which they are attached to form C3-6 cycloalkyl; Z1 is (un)substituted Ph, (un)substituted benzofuranyl, or (un)substituted benzopyranyl, and Z2 is a substituted N-containing heterocyclyl, (un)substituted Ph, etc.), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting intermediates 1-oxo-N-(piperidin-4-yl)-1,3-dihydroisobenzofuran-5-carboxamide hydrochloride and (4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetaldehyde. In the ROMK channel functional thallium flux assay, II had an IC50 of 0.01 μM. The experimental process involved the reaction of Methyl 5-amino-4-methylpicolinate(cas: 868551-99-9).Recommanded Product: 868551-99-9

The Article related to preparation piperidine derivative inhibitor renal medullary potassium channel, cardiovascular disease piperidine derivative inhibitor renal medullary potassium channel, edema treatment piperidine derivative inhibitor renal medullary potassium channel and other aspects.Recommanded Product: 868551-99-9

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 21, 2022, Rai, Roopa; Booth, Robert published a patent.COA of Formula: C9H14N2 The title of the patent was Preparation of 1H-pyrrolo[2,3-b]pyridine derivatives as PGDH inhibitors and inhalation formulations thereof. And the patent contained the following:

Disclosed are compounds that inhibit 15-hydroxy-prostaglandin dehydrogenase (PGDH) thus modulating prostaglandin levels which may be useful for the treatment of respiratory disorders such as COPD and idiopathic pulmonary fibrosis. Compounds of formula I [wherein R1 = (un)substituted C6-10aryl and 5- to 10-membered heteroaryl; R2 = H and R3 = CF3; R2 and R3 together = O; each R4 and R5 independently = halo, OH and derivatives, NH2 and derivatives, etc.; m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n = 1, 2, 3, or 4; p = 0, 1, 2, or 3] or pharmaceutically acceptable salts thereof, are claimed and exemplified. Example compound II was prepared from a multistep procedure (preparation given). Exemplified I were evaluated for PGDH inhibitory activity from which II demonstrated an IC50 of < 0.1μM. In some embodiments, the compounds disclosed herein are formulated for delivery via inhalation. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).COA of Formula: C9H14N2

The Article related to pyrrolopyridine carboxamide derivative preparation inhalant formulation, hydroxyprostaglandin dehydrogenase inhibitor preparation pulmonary fibrosis copd, benzimidazole azabenzimidazole indole benzoxazine carboxamide preparation prostaglandin inhibitor and other aspects.COA of Formula: C9H14N2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 15, 2014, Ghaffari, Behnaz; Preshlock, Sean M.; Plattner, Donald L.; Staples, Richard J.; Maligres, Peter E.; Krska, Shane W.; Maleczka, Robert E.; Smith, Milton R. published an article.Electric Literature of 1349171-28-3 The title of the article was Silyl Phosphorus and Nitrogen Donor Chelates for Homogeneous Ortho Borylation Catalysis. And the article contained the following:

Ir catalysts supported by ortho-(diisopropylsilyl)(di-p-tolylphosphino)benzene bidentate ligand that contains P- or N-donors, effects ortho-borylations for a range of substituted aromatics E.g., reaction of C6H5CO2Me with bis(pinacolato)diboron (B2pin2) in the presence of 1.25 mol% [Ir(OMe)(cod)]2/ 2.5 mol% (p-tol)2PC6H4-2-(SiHiPr2) in THF at 80° to give 72% yield of Me 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate. The substrate scope is broad, and the modular ligand synthesis allows for flexible catalyst design. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Electric Literature of 1349171-28-3

The Article related to ortho silylphosphinylbenzene tethered iridium cyclooctadiene preparation catalyst orthoborylation, crystal structure ortho silylphosphinylbenzene tethered iridium cyclooctadiene, mol structure ortho silylphosphinylbenzene tethered iridium cyclooctadiene and other aspects.Electric Literature of 1349171-28-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 31, 1979, Sadikov, A. S.; Otroshchenko, O. S.; Yunusov, T. K. published an article.Category: pyridine-derivatives The title of the article was Sulfur-containing derivatives of anabasine and its analogs. And the article contained the following:

Treatment of anabasine, isoanabasine and 2,3′-dipiperidyl with SOCl2, SCl2, elemental S, concentrated H2SO4, and sulfoacids of N heterocyclic bases gave a series of biol. active S-containing derivatives, e.g. I and II, of anabasine and its analogs. Dependences between the structure of substrates and their chem. reactivity were discussed. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Category: pyridine-derivatives

The Article related to anabasine reaction sulfur compound, isoanabasine reaction sulfur, dipiperidyl reaction sulfur, sulfur reaction anabasine, thionyl chloride reaction anabasine, sulfur chloride reaction anabasine, sulfuric acid reaction anabasine, sulfo acid reaction anabasine and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 10, 2021, Karges, Johannes; Kalaj, Mark; Gembicky, Milan; Cohen, Seth M. published an article.Reference of [2,2′-Bipyridine]-3,3′-diamine The title of the article was ReI tricarbonyl complexes as coordinate covalent inhibitors for the SARS-CoV-2 main cysteine protease. And the article contained the following:

Since its outbreak, the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has impacted the quality of life and cost hundreds-of-thousands of lives worldwide. Based on its global spread and mortality, there is an urgent need for novel treatments which can combat this disease. To date, the 3-chymotrypsin-like protease (3CLpro), which is also known as the main protease, is considered among the most important pharmacol. targets. The vast majority of investigated 3CLpro inhibitors are organic, non-covalent binders. Herein, the use of inorganic, coordinate covalent binders is proposed that can attenuate the activity of the protease. ReI tricarbonyl complexes were identified that demonstrate coordinate covalent enzymic inhibition of 3CLpro. Preliminary studies indicate the selective inhibition of 3CLpro over several human proteases. This study presents the first example of metal complexes as inhibitors for the 3CLpro cysteine protease. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Reference of [2,2′-Bipyridine]-3,3′-diamine

The Article related to rhenium tricarbonyl complex coordinate inhibitor main protease sars cov2, synthesis crystal structure rhenium tricarbonyl complex protease inhibitor 3clpro, sars-cov-2, antiviral agents, bioinorganic chemistry, medicinal inorganic chemistry, protease inhibitor and other aspects.Reference of [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Cheng, Jianjun; Deming, Timothy J. published an article in 1999, the title of the article was Enantioselective polymerization of 5-benzyl glutamate N-carboxyanhydride using chiral nickel(0) initiators.Application In Synthesis of 2-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)pyridine And the article contains the following content:

Enantioselective polymerization of 5-benzyl glutamate NCA was investigated using chiral bidentate nitrogen ligands in combination with a nickel zero initiation system. We found that ligands having mixed pyridine-oxazoline structures gave excellent control of mol. weight and narrow mol. weight distributions. Moderately high enantioselectivities were induced when chiral 2-pyridinyl oxazoline ligands were utilized. The highest enantioselectivity was found with (4S)-4-tert-butyl-(2-pyridinyl)-2-oxazoline. The experimental process involved the reaction of 2-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)pyridine(cas: 109660-12-0).Application In Synthesis of 2-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)pyridine

The Article related to polybenzyl glutamate preparation catalyst nickel, benzyl glutamate carboxyanhydride polymerization nickel catalyst, enantioselective polymerization catalyst nickel, pyridine ligand nickel polymerization catalyst, oxazoline ligand nickel polymerization catalyst and other aspects.Application In Synthesis of 2-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)pyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Mondal, Dipanjan; Sardar, Gopa; Kabra, Dinesh; Balakrishna, Maravanji S. published an article in 2022, the title of the article was 2,2′-Bipyridine derived doubly B- N fused bisphosphine-chalcogenides, [C5H3N(BF2){NCH2P(E)Ph2}]2 (E = O, S, Se): tuning of structural features and photophysical studies.Product Details of 75449-26-2 And the article contains the following content:

2,2′-Bipyridine based bisphosphine [C5H3N{N(H)CH2PPh2}]2 (1) and its bischalcogenide derivatives [C5H3N{N(H)CH2P(E)Ph2}]2 (2, E = O; 3, E = S; 4, E = Se) were synthesized, and further reacted with BF3·Et2O/Et3N to form doubly B-N fused compounds [C5H3N(BF2){NCH2P(E)Ph2}]2 (5, E = O; 6, E = S; 7, E = Se) in excellent yields. The influence of the P=E bonds on the electronic properties of the doubly B-N fused systems and their structural features were investigated in detail, supported by extensive exptl. and computational studies. Compound 6 exhibited a very high quantum yield of ϕ = 0.56 in CH2Cl2, whereas compound 7 showed a least quantum yield of ϕ = 0.003 in acetonitrile. D. functional theory (DFT) calculations demonstrated that the LUMO/HOMO of compounds 5-7 mostly delocalized over the entire π-conjugated frameworks. The involvement of PE bonds in the HOMO energy level of these compounds follows the order: PO < PS < PSe. Time-correlated single photon counting (TCSPC) experiments of compounds 5-7 revealed the singlet lifetime of 4.26 ns for 6, followed by 4.03 ns for 5 and a lowest value of 2.18 ns (τ1) and 0.47 ns (τ2) with a double decay profile for 7. The authors' findings provide important strategies for the design of highly effective B-N bridged compounds and tuning their photophys. properties by oxidizing phosphorus with different chalcogens. Compounds 5 and 6 have been employed as green emitters (λem = 515 nm) in fluorescent organic light-emitting diodes (OLEDs). For compound 5, doped into the poly(9-vinylcarbazole) (PVK) matrix with 5 wt% doping concentration, nearly 90 Cd m-2 luminance with 0.022% external quantum efficiency (EQE) was achieved. The best performance was observed for compound 6 doped into PVK by 1 wt% having a maximum luminance of 350 Cd m-2 and a similar EQE value. The experimental process involved the reaction of [2,2'-Bipyridine]-3,3'-diamine(cas: 75449-26-2).Product Details of 75449-26-2

The Article related to boron bipyridinylbisphosphinylchalcogenide complex preparation frontier mol orbital fluorescence lifetime, fluorescence oled redox potential boron bipyridinylbisphosphinylchalcogenide complex, crystal structure boron bipyridinylbisphosphinylchalcogenide complex and other aspects.Product Details of 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 9, 2006, Kelly, Michael G.; Kincaid, John; Kaub, Carl J. published a patent.Related Products of 39919-70-5 The title of the patent was Preparation of fused heterocyclic compounds for preventing and treating various diseases. And the patent contained the following:

The title compounds I [A, B = (un)substituted CH2, CO or CS; Y = (un)substituted CH2; W = CR4, N; Z = O, NR2; L = (hetero)alkylene; R1 = carbocyclyl or heterocyclyl; R2 = H, alkyl, cycloalkyl; R3 = carbocyclyl or heterocyclyl; R4 = H, alkyl, acyl, etc.; R5 = R4, Z’-L’-R4 (wherein Z’ = a bond, O, S, etc.; L’ = alkylene)], useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others, were prepared and formulated. E.g., a multi-step synthesis of II, starting from Et 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride, was given. The exemplified compounds I were tested in calcium uptake assay (P2X2 and P2X3) and % inhibition data were given for representative compounds I. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Related Products of 39919-70-5

The Article related to fused heterocycle pyridopyrimidinamine preparation purinoceptor antagonist analgesic antiinflammatory anxiolytic, cognition enhancer pyridopyrimidinamine preparation purinoceptor antagonist, antidepressant pyridopyrimidinamine preparation purinoceptor antagonist and other aspects.Related Products of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 31, 2013, Ueno, Hirokazu; Yamamoto, Takashi; Takashita, Ryuta; Yokoyama, Ryohei; Sugiura, Toshihiko; Kageyama, Shunsuke; Ando, Ayatoshi; Eda, Hiroyuki; Eviryanti, Agung; Miyazawa, Tomoko; Kirihara, Aya; Tanabe, Itsuya; Nakamura, Tarou; Noguchi, Misato; Shuto, Manami; Sugiki, Masayuki; Dohi, Mizuki published a patent.Application In Synthesis of 4-Bromo-2-isopropylpyridine The title of the patent was Preparation of N-(4-sulfonamidobenzoyl)-L-phenylalanine and N-(4-sulfonamidobenzoyl)-3-(pyridin-2-yl)-L-alanine derivatives as α4-integrin inhibitors. And the patent contained the following:

There are provided L-phenylalanine and 3-(pyridin-2-yl)-L-alanine derivatives having terminal sulfonamide groups and heterocyclic groups [I; A = Q, Q1, Q2; Arm = cycloalkane or aromatic ring containing 0-4 heteroatoms selected from O, S, and N; R1, R2, R3, R11, R12, R13, R14, R21, R22, R23, R24, R25 = group A, H, lower alkylamino, lower alkylamino-lower alkyl; group A = halo, HO, each hydroxy- or halo-(un)substituted lower alkyl, alkenyl, alkynyl, or alkylthio, NO2, NH2, CO2H, lower alkyloxycarbonyl, CONH2, lower alkanoyl, aroyl, lower alkylsulfonyl, SO2NH2, ammonium group; B = (un)substituted lower alkoxy, HO, hydroxyamino; R41 = H, lower alkyl; a, b, c, d = CR31, CR32, CR33, CR34; e, f, g, h = CR35, CR36, CR37, CR38; R31-R38 = H, halo, lower alkyl, lower alkoxy, NO2; wherein one or two of a, b, c, and d = N atom; one or two of e, f, g, and h = N atom; at least one of R31-R34 = halo or lower alkyl; D = each (un)substituted Ph or heterocyclyl; E = group A, lower alkylaminoalkylene, (un)substituted 5- or 6-membered heterocyclyl, or substituted CONH2; or lower alkylcarbonyl and lower alkyloxycarbonyl in E group are linked to Ph of D group to form a ring] or pharmaceutically acceptable salts thereof. These compounds have excellent α4-integrin-inhibiting activity with high selectivity for α4β7-integrin over α4β1-integrin. They are useful for the treatment or prevention of inflammatory diseases related to α4β7 integrin-dependent adhesion process. Thus, 100 mg Me 4-(1-methyl-2,4-dioxo-1,4-dihydropyrido[3,4-d]pyrimidin-3(2H)-yl)-L-phenylalaninate and 89.0 mg 2,6-difluoro-4-[[[5-(1H-1,2,4-triazol-1-yl)pyridin-2-yl]sulfonyl]amino]benzoic acid were suspended in 2.0 mL CH2Cl2, treated with 133 mg HATU and 0.160 mL diisopropylethylamine, stirred at room temperature for 2 h, and concentrated under reduced pressure to give, after purification using reversed phase HPLC, Me N-[2,6-difluoro-4-([[5-(1H-1,2,4-triazol-1-yl)pyridin-2-yl]sulfonyl]amino)benzoyl]-4-(1-methyl-2,4-dioxo-1,4-dihydropyrido[3,4-d]pyrimidin-3(2H)-yl)-L-phenylalaninate (II; R = Me) tris(trifluoroacetate). II.3CF3CO2H (R = Me) (25.0 mg) was treated with 2.0 mL 4 N HCl/dioxane solution and 2.0 mL H2O, stirred at 80° for 1 h, and concentrated to give, after purification using reversed phase HPLC, II.3CF3CO2H (R = H). II (R = H) (free base) inhibited the binding of MAdCAM to human RPMI-8866 cells expressing α4β7 integrin and that of MAdCAM to human RPMI-8866 cells expressing α4β1 integrin with IC50 of 0.060 and nM, resp., and 220-fold inhibition selectivity for α4β7 integrin. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Application In Synthesis of 4-Bromo-2-isopropylpyridine

The Article related to sulfonamidobenzoylhenylalanine preparation selective alpha 4 beta 7 integrin inhibitor, inflammatory disease treatment prevention sulfonamidobenzoylhenylalanine preparation, sulfonamidobenzoylpyridinylalanine preparation selective alpha 4 beta 7 integrin inhibitor and other aspects.Application In Synthesis of 4-Bromo-2-isopropylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem